(Alliance News) - GlaxoSmithKline PLC on Tuesday said the US Food & Drug Administration has granted a priority review for its biologics license application, which seeks approval of belantamab mafodotin.
The FTSE 100-listed drugmaker explained that belantamab mafodotin was created for the treatment of patients with relapsed or refractory multiple myeloma.
Multiple myeloma is blood cancer and is generally considered treatable, but not curable.
Glaxo said the application is based on data from the Dreamm-2 study, which enrolled "heavily" pre-treated patients who had actively progressing multiple myeloma.
The stock was trading 0.6% lower in London on Tuesday at 1,827.20 pence a share.
By Evelina Grecenko; evelinagrecenko@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
Glaxosmithkline (GSK)
